|Cells||Cor.4U® / vCor.4U® cardiomyocytes or co-cultures of cardiomyocytes with FibroCor.4U cardiac fibroblasts|
|Cell source||Human iPS cells of 26y/o Caucasian female|
|Service type||Functional / phenotypic analysis|
A study protocol will be sent to initiate the study. Results are sent as draft and final study report
Experimental run time: ~1.5 weeks per plate. Draft report: within 5 weeks.
- Cost-effective, robust and fast assay to assess toxicity/efficacy early in drug development
- Combines Cor.4U® , a well-characterized predictive cardiac model, with HTS capabilities
- Highly validated assay; part of the CiPA (Comprehensive in Vitro Proarrhythmia Assay) initiative
CardioFlux utilizes intracellular calcium transients and beat rate analysis of Cor.4U® human induced pluripotent stem (iPS) cell-derived cardiomyocytes to assess cardiac liability and efficacy of drug compounds.
Transient rise of cytosolic free calcium ion concentrations ([Ca2+ ]i ) plays a pivotal role in cardiomyocyte contraction. During the cardiac action potential, the rise and duration of these calcium transients [Ca2+ ]i are carefully controlled by a mechanism called the calcium-induced calcium release.
Direct acute drug effects, including interference with ion channels, pumps, exchangers and hormone receptors, or kinase-mediated signaling involved in regulation of the human cardiomyocyte action potential and heart rate control can be detected by monitoring [Ca2+ ]i transients, which makes it a valuable tool in drug discovery and safety pharmacology assessment.
In the ongoing CiPA validation study, calcium transient measurements are one of three methods to assess pro-arrhythmic effects on a subset of blinded compounds in Cor.4U® cardiomyocytes.
The CardioFlux assay has been validated with >75 compounds from a wide variety of compound classes.